Industry News
– Freenome’s comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 /PRNewswire/ — Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans. Freenome’s multiomics platform allows…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Electra Therapeutics, Inc., a clinical stage biotechnology company developing novel antibody therapies that target signal regulatory proteins (SIRP), today announced presentations and clinical progress for ELA026, the company’s first-in-class antibody in development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease. Three poster…
Read More
Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis,…
Read More
Oral presentation describes a unique APC nanobody library and its potential as a source for novel treatments to diseases including trauma, hemophilia, ischemia and sepsis. Excerpt from the Press Release: SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ — Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeted to…
Read More
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Biomea Fusion remains on track to file an IND for BMF-500 in the first half of 2023 Excerpt from the Press Release: REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing…
Read More
-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured by best response- -Participants with TR-aGVHD (11 of 12 concomitant ruxolitinib) achieved an ORR of 67% and CR of 25% at Day 28- -Median survival benefits in TR-aGVHD participants compare favorably to historical controlsneihulizumab was well tolerated, with similar safety…
Read More
Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus docetaxel in patients with metastatic non-small cell lung cancer (NSCLC)…
Read More
Excerpt from the Press Release: Collaboration employing Guardant360 CDx assay is first to use ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to first-line therapy progression PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration…
Read More
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activity and lysosomal function in the brain Excerpt from the Press Release: SOUTH SAN FRANCISCO,…
Read More
Excerpt from the Press Release: BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it has submitted an exploratory Investigational New Drug (eIND) application to the U.S. Food and Drug Administration (FDA) for a planned First-in-Human…
Read More